Home > PJ (current issue) > The Society | Search

The Pharmaceutical Journal
Vol 277 No 7419 p377
23 September 2006


Society summary

 Law and Ethics Bulletin

An occasional feature, prepared in the Royal Pharmaceutical Society’s Professional Standards Directorate, to highlight problems and inquiries currently being handled

Law and Ethics Bulletin, 2001 to present


Technical errors on Schedule 2 and 3 Controlled Drug prescriptions

Amendments to the Misuse of Drugs Regulations 2001 enable a pharmacist to make changes to prescriptions for Schedule 2 and 3 Controlled Drugs except temazepam (see below) in certain circumstances where the prescription does not comply with the CD prescription requirements but where the prescriber’s intentions are absolutely clear, provided that the pharmacist:

(a) Having exercised due diligence, is satisfied on reasonable grounds that the prescription is genuine;

(b) Having exercised all due diligence, is satisfied on reasonable grounds that he is supplying the drug in accordance with the intention of the person issuing the prescription;

(c) Amends the prescription in ink or otherwise indelibly to correct the minor typographical errors or spelling mistakes so that the prescription complies with Regulation 15 of the Misuse of Drugs Regulations 2001 (which requires the total quantity to be in both words and figures); and

(d) Marks the prescription so that the amendment he has made under subparagraph (c) is attributable to him.

The only errors that pharmacists may amend are:

(1) Minor spelling mistakes

(2) Minor typographical mistakes

(3) Where the total quantity of the preparation of the CD or the number of dosage units as the case may be is specified in either words or figures but not both, ie, either the words or the figures can be added to the CD prescription if one or the other has been omitted

There are currently no provisions for pharmacists to make changes other than those outlined above and where any other omissions or errors are made, eg, the prescriber has omitted the dose or strength, the prescription should be returned to the prescriber for amendment.

The pharmacist must ensure that the prescription is marked so that the amendment made is attributable to him or her. The Regulations do not specify exactly how the prescription should be marked. For example, a pharmacist may choose to write his or her name or registration number or signature on the prescription or could alternatively place an asterisk by the change and place a footnote on the prescription.

Where an amendment is made by one pharmacist (A) and a second pharmacist (B) makes a supply — for example, because there is an owing — both pharmacists must be satisfied of the integrity of the prescription. Although pharmacist B does not have to duplicate the amendment made by pharmacist A, they must satisfy themselves that the prescription is genuine and that they are supplying in accordance with the prescriber’s intention. The Home Office has stated that in this situation Pharmacist B should also mark the prescription to indicate that the amendment is attributable to himself as well as Pharmacist A.

Temazepam is excluded from this change because it is exempted from the CD prescription requirements (eg, requirement for total quantity to be expressed in words and figures) that apply to all other Schedule 2 and 3 CDs.

Back to Top


©The Pharmaceutical Journal